Analysis of CHK2 in patients with myelodysplastic syndromes

Leukemia Research

Volumn 26, Issue 11, 2002, Pages 985-987

  Aktas, Dilek ^a   Arno, Matthew J ^b   Rassool, Feyruz ^b   Mufti, Ghulam J ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

CDS1; CHK2; Mutations; Myelodysplastic syndromes; RAD53

Indexed keywords

ARGININE; CHECKPOINT KINASE 2; LYSINE; MESSENGER RNA; PROTEIN; PROTEIN KINASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; CHROMOSOME 17P; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATION; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MARROW; DNA PRIMERS; DNA REPLICATION; GENE DELETION; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; POINT MUTATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0036843363     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00075-9     Document Type: Article

References (16)

1. Mufti G.J. A guide to risk assessment in the primary myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 6:1992;587-606.
2. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodyplastic syndromes. Semin. Hematol. 33:1996;127-138.
3. Neubauer A., Dodge R.K., George S.L., Davey F.R., Silver R.T., Schiffer C.A.et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 83:1994;1603-1611.
4. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
5. Jonveaux P., Fenaux P., Quiquandon I., Pignon J.M., Lai J.L., Loucheux-Lefebvre M.H.et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 6:1991;2243-2247.
6. Fenaux P., Preudhomme C., Quiquandon I., Jonveaux P., Lai J.L., Vanrumbeke M.et al. Mutations of the p53 gene in acute myeloid leukaemia. Br. J. Heamatol. 80:1992;178-183.
7. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E.et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531.
8. Malkim D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H.et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
9. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282:1998;1893-1897.
10. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCdsl functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14:2000;278-288.
11. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10389-10394.
12. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:2000;289-300.
13. Lai J.L., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Lepelley P.et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia. 9:1995;370-381.
14. Haruki N., Saito H., Tatematsu Y., Konishi H., Harano T., Masuda A.et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res. 60:2000;4689-4692.
15. Kimura K., Shinmura K., Yoshimura K., Shimizu K., Katai H., Beppu Y.et al. Absence of germline CHK2 mutations in familial gastric cancer. Jpn. J. Cancer Res. 91:2000;875-879.
16. Hofmann W.-K., Miller C.W., Tsukasaki K., Tavor S., Ikezoe T., Hoezler D.et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk. Res. 25:2001;333-338.